Business Daily Media

Men's Weekly

.

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results - New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

HONG KONG SAR - Media OutReach Newswire - 22 April 2025 - CK Life Sciences Int'l., (Holdings) Inc. ("the Company") announced that the Company will be presenting new data from its cancer vaccine research pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.



The AACR Annual Meeting is a gathering central to the global cancer research community, bringing together scientists, clinicians, other healthcare professionals, survivors, patients and advocates every year to share the latest breakthroughs and developments in cancer science and medicine. Last year, the 2024 Annual Meeting attracted 23,000 in-person attendees and 6,700 online participants from 78 countries.

In recent years, CK Life Sciences has regularly participated at the AACR Annual Meeting. The 2025 Annual Meeting will be held from 25-30 April. At the event, CK Life Sciences will exhibit posters highlighting data from preclinical studies of investigational cancer vaccines programs targeting (i) PRAME (Preferentially Expressed Antigen in Melanoma), (ii) PD-L1 (programmed cell death ligand 1), (iii) B7-H3 (B7 homolog 3) and (iv) Claudin 6 proteins, respectively.

PRAME is a protein highly expressed in several cancers, including melanoma, liver cancer and leukemia.

PD-L1 is one of the most important immune checkpoint proteins that is highly expressed in cancer cells to block T cell activation in the tumour microenvironment.

B7-H3 is another immune checkpoint protein that modulates T cell responses and is often overexpressed in cancer.

Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in cancers like breast cancer, lung cancer and endometrial cancer, where it is associated with tumour progression and metastasis.

In addition, CK Life Sciences will be co-presenting with our research collaborator two posters showcasing our Artificial Intelligence (AI)-empowered platform for designing cancer vaccines.

"CK Life Sciences is pleased with the preclinical efficacy results of its investigational cancer vaccines targeting PRAME, PD-L1, B7-H3 and Claudin 6 proteins, and we hope to further advance the research & development of these and other cancer vaccines. We are also excited about the progress achieved in our efforts to develop an AI platform aimed at designing cancer vaccines that are more likely to be immunogenic and clinically effective," said Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences.

Dr. Toh continued, "CK Life Sciences is determined to accelerate its R&D to benefit cancer patients. Currently, a number of therapeutic cancer vaccines are in clinical and discovery/preclinical research stages. Amongst them, seviprotimut-L, a cancer vaccine already in the final research stage, is being tested for the adjuvant treatment of stage IIB or IIC melanoma following definitive surgical resection.

DETAILS ON POSTER PRESENTATIONS:

  • Abstract 853: PDL1-PRAME dual antigen cancer vaccine inhibits melanoma growth in syngeneic mouse model and induces antigen-specific immune responses
Authors: Kin-Tak Chan, Hsin-Wei Chen, Pi-Hui Liang, You-Yu Lin, Tristan Zhang, Melvin Toh

Session Category: Clinical Research
Session Title: Vaccines and Cell Therapies
Session Date and Time: 4/27/2025 2:00 PM - 5:00 PM
Location: Poster Section 35
Poster Board Number: 9

  • Abstract 3533: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model
Authors: Na Wang, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 9

  • Abstract 3536: Synergistic effects of combined PD-L1 and B7-H3 fusion protein vaccination in a mouse model of pancreatic cancer
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 12

  • Abstract 3538: The development of neoantigen-derived peptide vaccine driven by AI epitope design and computer assisted epitope enhancement
Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Jiewen Du, Lipeng Lai, Melvin Toh

Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 39
Poster Board Number: 14

  • Abstract 3649: Artificial intelligence accelerates shared neoantigen peptide cancer vaccine development
Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Chi Han Samson Li, Kin Tak Chan, Hong Wang, Melvin Toh, Lipeng Lai

Session Category: Bioinformatics/ Computational Biology/ Systems Biology/ Convergent Science
Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
Session Date and Time: 4/28/2025 2:00 PM - 5:00 PM
Location: Poster Section 45
Poster Board Number: 11

The full abstracts are available in the AACR Online Itinerary Planner, which can be accessed at: https://www.abstractsonline.com/pp8/#!/20273

DISCLAIMER
This press release may contain forward-looking statements regarding the Group’s research and development projects which may involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements.
All information in this press release is for general reference only and is not intended as investment advice or medical advice. CK Life Sciences Int'l., (Holdings) Inc. does not warrant or represent, express or implied, as to the accuracy, completeness or updated status of such information. No liability will be accepted for any loss or damage howsoever arising from or in reliance upon such information.

Copyright ©2025 CK Life Sciences Int’l., (Holdings) Inc. All rights reserved.

Hashtag: #CKLifeSciences #CancerVaccines #R&D #Pharmaceutical #AmericanAssociationforCancerResearch #AACR #PRAME #PD-L1 #B7-H3 #Claudin6Proteins #Melanoma #AI

The issuer is solely responsible for the content of this announcement.

News from Asia

Star Living’s New Electronic Product Line Debuts Across Showrooms in May

SINGAPORE - Media OutReach Newswire - 21 May 2025 - Star Living, a home furnishing brand in Singapore, is proud to announce its expansion into the electronic product category this May...

Wildberries marketplace begins to offer products from UAE sellers

DUBAI, UAE – Media OutReach Newswire – 21 May 2025 – Wildberries, a leading e-commerce platform in Eurasia, has expanded its product offering to include products from sellers based in the United A...

CHAGEE's Signature Drink Gets a Meaningful Makeover: Introducing BO·YA JASMINE GREEN MILK TEA

In time for International Tea Day on 21 May, CHAGEE reintroduces its bestselling drink — with a new name that reflects its essence. SINGAPORE - Media OutReach Newswire - 21 May 2025 - This Interna...

1 in 4 Malaysians at Risk: Alpro Pharmacy Leads National Movement to Reverse Prediabetes

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 21 May 2025 - With one in four Malaysian adults unknowingly living with prediabetes, the country is facing a silent but escalating health crisis...

XTransfer Named Among The Top 100 Cross-Border Payments Companies for 2025 by FXC Intelligence

HONG KONG SAR - Media OutReach Newswire - 20 May 2025 - XTransfer, the world's leading and China's No.1 B2B Cross-Border Trade Payment Platform, has been named for the first time to FXC Intellig...

Space-tech Innovator Tenchijin Participated in "TECHNOMART Malaysia" at Malaysia Pavilion, Osaka-Kansai EXPO, Building Partnerships with Malaysian Companies

OSAKA, JAPAN - Media OutReach Newswire - 21 May 2025 - Tenchijin Inc., a space-tech innovator, showcased its innovative solutions at "TECHNOMART Malaysia-Japan: B2B Session on the Space Industry" ...

Federation of Thai Industries, Petrochemical Industry Club (FTIPC) hosts the Asia Petrochemical Industry Conference 2025 (APIC 2025) under the theme "Ensuring a Transformed World Prosperity", driving Asia’s petrochemical industry toward global sustainabil

BANGKOK, THAILAND - Media OutReach Newswire - 21 May 2025 - Federation of Thai Industries, Petrochemical Industry Club (FTIPC), proudly represented Thailand as host of the Asia Petrochemical Indus...

InvestHK promotes Hong Kong as Asia’s business launchpad in Istanbul

HONG KONG SAR - Media OutReach Newswire - 13 May 2025 - Invest Hong Kong (InvestHK), the Hong Kong government's investment promotion arm, announced today (12 May 2025) that Ms Alpha Lau, Director-...

Largest China-Russia Land Port Reinvents Itself as Industrial Hub

HOHHOT, CHINA - Media OutReach Newswire - 21 May 2025 - As China's largest land port, Manzhouli is expanding beyond its traditional role as a "transit station." By promoting local processing of gr...

Global Water Crisis Knows No Borders: Malaysia Leads Call For Urgent Cooperation

PARIS, FRANCE - Media OutReach Newswire - 13 May 2025 - Malaysia calls on the international community to strengthen cooperation in addressing the global water crisis – a transboundary challenge im...

Sleep Soundly, Knowing Your People Are Paid Right: Navigating the Complexities of Modern Payroll

The Role of Modern Payroll Modern payroll systems are essential to any organization's financial infrastructure in today's rapidly evolving business...

Tariffs for dummies: Getting to grips with the business of exporting goods and services

It pays to understand how the international taxation system works before you start selling abroad. Take a glance at the business news just now an...

Deputy Unveils Enterprise-Grade Analytics+ to Power Smarter Workforce Decisions for Shift-Based Businesses

Deputy, the world’s leading workforce management platform for shift work, today announced the global launch of Deputy Analytics+, a next-generatio...

UNSW startup accelerator offers $200K to the next generation of Australian deeptech unicorns

UNSW Founders, Australia’s most recommended startup accelerator, has partnered with fund manager Luminary Partners to invest $200,000 each into 18...

The Future Is Now: AI Modernization Is Reshaping How Business Gets Done

The present business environment imposes stronger requirements on Australian organizations to match the fast-paced digital-first economy requireme...

Businesses losing an average of $493k from data integrity flaws

Managing data responsibly and effectively for the AI age can give organisations a strong competitive advantage, but many are failing to harness th...

Sell by LayBy